MaaT Pharma

MaaT bags €18M to test microbiome modulators in cancer patients
MaaT bags €18M to test microbiome modulators in cancer patients
Fierce Biotech
MaaT Pharma
solid tumors
graft vs host disease
Flag link:
Microbiome Report for Week Ending 5/11/19
Microbiome Report for Week Ending 5/11/19
CP Wire
icrobiome
Vedanta Biosciences
MaaT Pharma
Acute GvHD
patents
Flag link:
Microbiome Report for Week Ending 5/11/19
microbiome
Vedanta Biosciences
MaaT Pharma
Acute GvHD
patents
Flag link:
Microbiome Report for Week Ending 4/13/19
Microbiome Report for Week Ending 4/13/19
CP Wire
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
Flag link:
Microbiome Report for Week Ending 4/13/19
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
Flag link:
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
CP Wire
MaaT Pharma
graft vs host disease
MaaT013
Flag link:
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
MaaT Pharma
graft vs host disease
MaaT013
Flag link:
MaaT Pharma Releases Results Of Microbiome Restoration Therapy in Acute Myeloid Leukemia Patients
MaaT Pharma Releases Results Of Microbiome Restoration Therapy in Acute Myeloid Leukemia Patients
CP Wire
MaaT Pharma
acute myeloid leukemia
microbiome
Flag link:
MaaT Pharma Releases Results Of Microbiome Restoration Therapy in Acute Myeloid Leukemia Patients
MaaT Pharma
acute myeloid leukemia
microbiome
Flag link:
MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
CP WIre
microbiome
MaaT Pharma
Flag link:
MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic
MaaT Pharma
Flag link: